MicroRNAs (miRNAs) are global RNA regulators and important master controllers of the cell survival and proliferation pathways that are critically important in cancer development and tumor maintenance. Recent evidence from our group and others show that miRNA binding site polymorphisms in the 3'untranslated regions (3'UTRs) of mRNAs can strongly impact cancer risk, and that miRNA expression patterns in tumors are important biomarkers of outcome and treatment response. We hypothesize that advances in miRNA understanding can be applied to breast cancer. Breast cancer has 3 main sub-types based on expression of the receptor molecules ER (estrogen), PR (progesterone) and HER2/neu. Breast cancers negative for all of these receptors (triple negative breast cancer [TNBC]) have the worst outcome, and little is known about the etiology and risk factors for this sub-type. We hypothesize that advances in the novel area of miRNA biology can be applied to TNBC to identify novel biomarkers of risk and outcome as well as understand fundamental mechanisms of disease. The overall goal of this proposal is to study miRNA 3'UTR polymorphisms as initiating events in breast cancer, and to define the predictive role of miRNA expression patterns to identify biomarkers of response to therapy and outcome. We will ultimately test our findings that 3'UTR polymorphisms and misregulated miRNAs are key in breast cancer development using in vivo xenograft and transgenic mouse models. By accomplishing these aims we will be able to appropriately risk stratify women for the risk of developing breast cancer, as well as identify biomarkers predicting their response to therapy and ultimate outcome. We expect to gain insight into the fundamental biology behind breast cancer development, and to further identify miRNAs that are new targets in breast cancer response, to make significant strides towards personalized medicine for women.

Public Health Relevance

Breast cancer is a common disease, with certain subtypes being very aggressive with poor outcome, such as triple negative breast cancer. While breast cancer for most women is likely due to multifactorial causes, there is a suspected inherited risk for some proportion of breast cancer cases, yet most of the genetic causes remain unknown. Through our understanding of breast cancer as well as microRNAs we have identified new biomarkers of breast cancer risk, which we believe will likely also be biomarkers of response to therapy, and will allow us to better prevent and treat breast cancer for women in the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA157749-02
Application #
8497634
Study Section
Cancer Biomarkers Study Section (CBSS)
Program Officer
Wang, Wendy
Project Start
2012-07-01
Project End
2017-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
2
Fiscal Year
2013
Total Cost
$324,677
Indirect Cost
$129,627
Name
Yale University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Saridaki, Zenia; Weidhaas, Joanne B; Lenz, Heinz-Josef et al. (2014) A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Clin Cancer Res 20:4499-510
Nath, Sameer K; Chen, Zhe J; Rowe, Bryan P et al. (2014) A PHASE II TRIAL OF BALLOON-CATHETER PARTIAL BREAST BRACHYTHERAPY OPTIMIZATION IN THE TREATMENT OF STAGE 0, I AND IIA BREAST CARCINOMA. J Radiat Oncol 3:371-378
Chung, C H; Lee, J W; Slebos, R J et al. (2014) A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol 25:2230-6
Jiao, Alan L; Slack, Frank J (2014) RNA-mediated gene activation. Epigenetics 9:27-36
Lee, Larissa J; Ratner, Elena; Uduman, Mohamed et al. (2014) The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905. PLoS One 9:e94167
Dorairaj, Jemima J; Salzman, David W; Wall, Deirdre et al. (2014) A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer. BMC Cancer 14:421
Adams, Brian D; Kasinski, Andrea L; Slack, Frank J (2014) Aberrant regulation and function of microRNAs in cancer. Curr Biol 24:R762-76
Preskill, Carina; Weidhaas, Joanne B (2013) SNPs in microRNA binding sites as prognostic and predictive cancer biomarkers. Crit Rev Oncog 18:327-40
Salzman, David W; Weidhaas, Joanne B (2013) SNPing cancer in the bud: microRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. Pharmacol Ther 137:55-63
Slack, Frank J (2013) MicroRNAs regulate expression of oncogenes. Clin Chem 59:325-6